EHE

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.

Key Points: 
  • The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
  • “This early look at the IK-930 dose escalation data strongly supports our differentiated approach to targeting the Hippo pathway.
  • Importantly, following the target biology and initially focusing on EHE has allowed us to observe clinical activity of IK-930 early in our dose escalation.
  • Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023.

Nectar Life Sciences, the Health Technology Company Behind the First Hybrid, Vertically-Integrated Allergy Care Platform, Opens First Nectar Allergy Center in New York City

Retrieved on: 
Monday, August 28, 2023

Nectar Life Sciences , the trusted health technology company behind the first hybrid, vertically-integrated allergy care platform, today announced the grand opening of its flagship Nectar Allergy Center , located in New York City.

Key Points: 
  • Nectar Life Sciences , the trusted health technology company behind the first hybrid, vertically-integrated allergy care platform, today announced the grand opening of its flagship Nectar Allergy Center , located in New York City.
  • Nectar’s care offerings are now expanding from environmental allergies to more complex allergic conditions, including asthma, food allergies, and eczema.
  • Dr. Akansha Ganju, M.D., has also joined the company as Medical Director of the Nectar Allergy Center.
  • Increasing accessibility to comprehensive allergy care is a core part of Nectar Life Sciences’s mission, so the Allergy Center is strategically located near many subway and bus stops.

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Retrieved on: 
Monday, April 17, 2023

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will present preclinical data in two poster presentations highlighting the Company’s novel Hippo pathway inhibitor, IK-930, at the American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, FL from April 14-19, 2023.

Key Points: 
  • Data being shared today reveals that IK-930 selectively binds and inhibits TEAD1 and further describes the mechanism for its antitumor activity.
  • Key advantages demonstrated in the nonclinical studies include IK-930’s superior tolerability and comparable antitumor activity compared to panTEAD inhibition, resulting in a significantly improved projected therapeutic window in cancer patients.
  • IK-930 was designed as a TEAD1-selective inhibitor to avoid on-target renal toxicity expected from panTEAD inhibition.
  • TEAD1 is the most highly expressed TEAD paralog in mesothelioma and epithelioid hemangioendothelioma (EHE).

Collaborative Research Promotes Thomas Rodriguez-Schucker to President

Retrieved on: 
Wednesday, March 1, 2023

AUSTIN, Texas, March 1, 2023 /PRNewswire/ -- Collaborative Research, a strategic planning health care firm supporting local public health, social-service and community-based organizations for the past 20 years, today announced the appointment of Thomas Rodriguez-Schucker to President. The news comes as Founder and CEO Jeff Daniel steps away to focus on the launch of the Collaborative Research Foundation, a new 501c3 non-profit that will roll out in Q4 of 2023.

Key Points: 
  • AUSTIN, Texas, March 1, 2023 /PRNewswire/ -- Collaborative Research , a strategic planning health care firm supporting local public health, social-service and community-based organizations for the past 20 years, today announced the appointment of Thomas Rodriguez-Schucker to President.
  • The news comes as Founder and CEO Jeff Daniel steps away to focus on the launch of the Collaborative Research Foundation, a new 501c3 non-profit that will roll out in Q4 of 2023.
  • "As we continue the hard work of bringing an End to the HIV Epidemic, there is no better leader than Thomas to drive Collaborative Research's continued focus on that mission.
  • "It's all the more exciting as Jeff moves forward with the Collaborative Research Foundation, which will raise the bar for delivering exceptional prevention and care on a national level and will further our collective mission to End the HIV Epidemic."

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, November 7, 2022

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the third quarter ended September 30, 2022. The Company also shared updates across its pipeline, including highlighting the data from the Society for Immunotherapy of Cancer Conference (SITC) abstract released this morning from the IK-175 clinical program in urothelial carcinoma.

Key Points: 
  • It has been an extremely productive time for us in our targeted oncology efforts as well, with our RAS pathway development candidate coming shortly, and advancing our TEAD program.
  • Research and development expenses were $18.9 million and $13.4 million for the three months ended September 30, 2022 and 2021, respectively.
  • General and administrative expenses were $5.4 million and $4.9 million for the three months ended September 30, 2022 and 2021, respectively.
  • Ikena Oncologyis focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Retrieved on: 
Wednesday, October 26, 2022

These data reinforce our belief that the Hippo pathway is often activated as a critical resistance mechanism to other targeted therapies, and that IK-930 has the potential to overcome therapeutic resistance, said Jeffrey Ecsedy, Ph.D., Chief Development Officer of Ikena.

Key Points: 
  • These data reinforce our belief that the Hippo pathway is often activated as a critical resistance mechanism to other targeted therapies, and that IK-930 has the potential to overcome therapeutic resistance, said Jeffrey Ecsedy, Ph.D., Chief Development Officer of Ikena.
  • Multiple combination cohorts are planned, the first of which will be assessing IK-930s impact on resistance to EGFR inhibitors.
  • Ikena is advancing IK-930 both as a monotherapy in patients with Hippo pathway mutated cancers and in combination with other approved targeted therapies to combat therapeutic resistance.
  • Ikena Oncologyis focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Retrieved on: 
Tuesday, October 18, 2022

BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today provided a research & development update on the Company’s lead targeted oncology program in TEAD inhibition. Ikena also announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for the evaluation of TAGRISSO® (osimertinib), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with Ikena’s IK-930 as treatment for patients with EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

Key Points: 
  • The ongoing IK-930 clinical trial has planned cohorts exploring combinations with targeted therapies in which treatment-induced activation of the Hippo pathway may drive resistance.
  • Ikena OncologyTM is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.
  • The Companys lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies.
  • The Companys ongoing discovery research spans other targets in the Hippo pathway as well as the RAS signaling pathway.

EHE Health Partners with Danone North America, Underscoring Danone's Ongoing Commitment to Employee Health and Wellbeing

Retrieved on: 
Tuesday, August 30, 2022

NEW YORK and BROOMFIELD, Colo., Aug. 30, 2022 /PRNewswire/ -- Today, EHE Health, a national healthcare provider, and Danone North America, the purpose-driven food and beverage leader with a diverse portfolio of dairy and plant-based brands, announced a new three-year relationship to facilitate prevention at scale and drive better health outcomes for Danone's U.S.-based workforce. As one of the world's largest Certified B Corporations®, Danone is guided by its responsibility to use its business as a force for good, which includes its efforts to prioritize employee wellbeing.

Key Points: 
  • "Partnering with EHE Health will help increase engagement of these critical health services, especially amid the ongoing pandemic.
  • The new offering complements Danone's existing efforts to advance employee wellbeing, which helps contribute to its best-in-class culture and engaged workforce.
  • Through the partnership, Danone North America's more than 6,000 employees and their spouses/domestic partners who have chosen Cigna as their health insurance carrier will have access to EHE's newly announced Pulse by EHE Health mobile application.
  • "We're excited to partner with Danone to provide our premium preventive health services," said Dr. David Levy, MD and Chief Executive Officer of EHE Health.

EeroQ Raises $7.25M in Funding Led by B Capital’s Ascent Fund to Build Scalable Quantum Computer With Ethical Focus

Retrieved on: 
Tuesday, August 23, 2022

Scaling from one to thousands of quality qubits is made easier by our use of todays standard fabrication process, CMOS.

Key Points: 
  • Scaling from one to thousands of quality qubits is made easier by our use of todays standard fabrication process, CMOS.
  • B Capital led the funding round from its first dedicated early-stage fund Ascent Fund II.
  • This effort has been led by EeroQ Co-Founder Faye Wattleton , an internationally known leader in board governance and public policy.
  • EeroQ has developed research on ethical frameworks for responsible use beginning in 2018, and will continue to advocate for early ethical considerations.

EHE Health Launches Partnership with Cedar Gate Technologies to Offer Employers Unparalleled Insights

Retrieved on: 
Tuesday, August 9, 2022

NEW YORK, Aug. 9, 2022 /PRNewswire/ -- Today, EHE Health, the national leader in preventive care, and Cedar Gate Technologies, a leading value-based care software and technology services company, announced a strategic partnership to offer EHE's US-based clients value-based care analytics to help them better understand and respond to their workforce's overall health status. Through Cedar Gate's solution, EHE Health will be able to support their clients to make more effective decisions when it comes to their employees' health care.

Key Points: 
  • Through Cedar Gate's solution, EHE Health will be able to support their clients to make more effective decisions when it comes to their employees' health care.
  • "We're proud to partner with Cedar Gate to help bring our clients unmatched analytics when it comes to their population's health," said Greg Mansur, Chief Strategy Officer of EHE Health.
  • For 109 years, EHE Health has been an innovator and leader in helping people live longer, healthier lives with personalized preventive care.
  • Cedar Gate enables payers, providers, employers, and service administrators to excel at value-based care.